ReviewCurrent treatment options in oncology2022
Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy.
Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 52 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study for the Evaluation of the Degree of Skin Satisfaction of Cosmetics Creams PB-011 and PB-012 for Sensitive Skin in Oncological Patients Affected by a Palmoplantar Polyneuropathy Secondary to Chemotherapy or Chemotherapeutic Agents' Fusion to Monoclonal Antibodies (Immunocitostatics)
Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (daance): a multicenter trial
Who cites it
52 citing papers in PubMed, 5 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Efficacy of scrambler therapy in chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Research trends of acupuncture therapy for painful peripheral nervous system diseases from 2004 to 2023: a bibliometric and meta-analysis.Frontiers in neurology · 2025Pooled it
- Acupuncture in the treatment of chemotherapy-induced peripheral neuropathy: a meta-analysis and data mining.Frontiers in neurology · 2024Pooled it
- The effectiveness and safety of acupuncture for chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis.Integrative cancer therapiesPooled it
- A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Trial
- Trial
- Neurologic dance training and home exercise improve motor-cognitive dual-task function similarly, but through potentially different mechanisms, among breast cancer survivors with chemotherapy-induced neuropathy: Initial results of a randomized, controlled clinical trial.Journal of Alzheimer's disease : JAD · 2025Trial
- The effect of hand and foot exercises on peripheral neuropathy and quality of life in women with breast cancer: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Rhythmic Foot Embrocation According to Wegman/Hauschka for Alleviating Symptoms of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial.Integrative cancer therapiesTrial
- Proteomic Adaptations in the Spinal Cord of a Breast Cancer Model of Paclitaxel-Induced Peripheral Neuropathy.Journal of proteome research · 2026Article
- Effect of tango versus exercise on chemotherapy-induced neuropathy after breast cancer treatment: a Phase II randomized controlled trial.Research square · 2026Article
- Gut microbiota and metabolite disruption during breast cancer chemotherapy is associated with peripheral neuropathy sensory symptoms and pain.Brain, behavior, and immunity · 2026Article
- Gut Microbiota Dysbiosis and CIPN: State-of-the-Art Evidence and a Microbiota-Ozone Therapeutic Framework.Cancers · 2026Review
- Degraded myelin is associated with cold hypersensitivity in paclitaxel-induced peripheral neuropathy.bioRxiv : the preprint server for biology · 2026Article
- Evolving Paradigms in Cancer Pain Management: From Opioid-Centric Care to Multimodal and Personalized Strategies.Cancers · 2026Review
- Deep Learning-Assisted Differentiation of Four Peripheral Neuropathies Using Corneal Confocal Microscopy.Annals of clinical and translational neurology · 2026Article
- Patient and Clinician Views on Risk Prediction for Chemotherapy-Induced Peripheral Neuropathy.Journal of pain & palliative care pharmacotherapy · 2026Article
- Article
- Chemotherapy-induced neuropathy (CIN) persists chronically for most individuals with breast cancer who develop the condition: A survey study.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
opinion statementChemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and other specific agents. The long-term consequences of this condition can result in decreased patient quality of life and can lead to reduced dose intensity, which can negatively impact disease outcomes. There are currently no evidence-based preventative strategies for CIPN and only limited options for treatment. However, there are several strategies that can be utilized to improve patient experience and outcomes as more data are gathered in the prevention and treatment setting. Before treatment, patient education on the potential side effects of chemotherapy is key, and although trials have been limited, recommending exercise and a healthy lifestyle before and while undergoing chemotherapy may provide some overall benefit. In patients who develop painful CIPN, our approach is to offer duloxetine and titrate up to 60 mg daily. Chemotherapy doses may also need to be reduced if intolerable symptoms develop during treatment. Some patients may also try acupuncture and physical therapy to help address their symptoms, although this can be limited by cost, time commitment, and patient motivation. Additionally, data on these modalities are currently limited, as studies are ongoing. Overall, approaching each patient on an individual level and tailoring treatment options for them based on overall physical condition, their disease burden, goals of care and co-morbid health conditions, and willingness to trial different approaches is necessary when addressing CIPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.